Fast growing Scottish biotech company Sistemic Ltd today announced that it had closed a series A funding round with lead investors ChimeraBio and the Scottish Enterprise Scottish Co-Investment Fund.
The company will use the funding to further develop its proprietary SistemRNA compound-centric drug discovery technology. Using SistemRNA shortens the odds in drug discovery by enabling far more accurate prediction of potential drug indications, interactions and side effects.
SistemRNA screens compounds of interest against Sistemic’s knowledgebase of reference compound responses in cell-based models. The process generates information on biological differences, mechanism of action and potential new targets from the associated miRNA expression profiles referenced against the knowledgebase.
According to Sistemic CEO Chris Hillier, miRNA is increasingly seen as key to understanding drug efficiency: “We are able to rapidly release significant asset value for pharma and biotech partners. In addition to de novo discovery, there are major opportunities in repositioning, re-purposing and lifecycle extensions. For example, new indications, formulations and combinations of previously marketed products accounted for 45% of new medicines launched in 2007. Our first contracts have been in oncology but this is a broadly applicable approach. The new funding will enable us to expand our knowledgebase, for example, in cardiac and anti-inflammatory indications, and to accelerate commercial operations.”
Chairman and Partner of ChimeraBio, lead investor, Jim Reid commented: ”I am delighted with Sistemic’s rapid progress. In less than a year they have completed key technical milestones, secured their first contracts and began commercial operations in Boston to serve the key US market. With the strong and experienced management team led by Chris Hillier, I look forward to their continued growth as one of Scotland’s most dynamic new wave of biotech companies.” Andrew Sloane, head of Scottish Co-Investment Fund for Scottish Enterprise, said, “Scottish Enterprise has in important role to play in helping increase private sector investment into Scottish companies. This deal is a great example of how we have worked with private investors to make this happen. “Access to equity investment is extremely important for innovative Scottish companies like Sistemic, and this investment will help the company to further develop its capabilities in the field of drug discovery technology.”
Glasgow, United Kingdom; 22nd October 2018: Sistemic Ltd. is pleased to announce the completion of a Global Service and License Agreement for its SistemPSCCheck™ assay with Australian stem cell and regenerative medicine company, Cynata Therapeutics Ltd. The agreement will see the use of the SistemPSCCheck™ assay for the assessment of residual pluripotent stem cells in Cynata’s current iPSC-derived MSC clinical candidate CYP-001, as well other planned iPSC-derived MSC products.
We are looking for 2 life sciences graduates to support development of our new SistemPSCCheck™ v1.0 service product. These are 12 month placements, with the potential to develop into a permanent roles. For full information, please visit Scotgrad via the links below:
Sistemic will be attending the 4th Cell Therapy Conference: Manufacturing and Testing of Pluripotent Stem Cells in June to highlight the development of SistemPSCCheck™ - the world’s first commercial assay for assessment of pluripotent stem cell contamination in derived cell therapy products
GLASGOW, SCOTLAND Sistemic will be attending Phacilitate Cell & Gene Therapy World and the World Stem Cell Summit in January to highlight the development of their assay for assessment of pluripotent stem cell contamination in derived cell therapy products
Glasgow, SCOTLAND. Sistemic Ltd. is excited to announce significant progress with the development of a miRNA-based assay for assessment of pluripotent stem cell (PSC) contamination in derived cell therapy products. The development is being undertaken in conjunction with LGC, the UK National Measurement Laboratory and Designated Institute for chemical and bio-measurement.